Inotek Pharmaceuticals (ITEK) announced that it has completed enrollment in its Phase 3 clinical trial, MATrX-1, evaluating lead product candidate trabodenoson for the treatment of glaucoma. The primary endpoint is the reduction in intraocular pressure (IOP) over three months of treatment versus placebo. Top-line results from the trial are scheduled to be announced in December.